Table 2. Baseline Patient Characteristics^a.

At baseline, the mean age of subjects was 60 years old and the mean medication use was just over 2 years in both groups. The mean total UPDRS score in subjects randomized to DBS+ODT was 3 points higher than subjects randomized to ODT; mean UPDRS-III scores were nearly equal.

Characteristic	ODT (n=15)	ODT+DBS (n=15)
Gender
Male	13	14
Female	2	1
Age (yrs) at Enrollment
Mean	60 ± 7.0	60 ± 6.8
Range	51 - 69	52 - 74
Baseline Medicine Use
Mean Duration (yrs)	2.1 ± 1.1	2.2 ± 1.4
Mean L-dopa equivalents (mg/day)b	569 ± 389	451 ± 304
Baseline UPDRS Score
Mean Total	36 ± 15	39 ± 14
Mean UPDRS-III	15 ± 7.6	15 ± 8.5

^aReprinted from PD Charles, RM Dolhun, CE Gill, TL Davis, MJ Bliton, MG Tramontana, RM Salomon, L Wang, P Hedera, FT Phibbs, JS Neimat, PE Konrad, Deep brain stimulation in early Parkinson's disease: Enrollment experience from a pilot trial, 18 / 3, 268-73, 2011, with permission from Elsevier.

^b100 mg of Levodopa with a dopa-decarboxlase inhibitor = 130 mg of controlled-release Levodopa reparations = 83 mg of Levodopa with dopa-decarboxylase and COMT inhibitors = 1 mg of pergolide, pramipexole or lisuride = 3 mg of ropinirole [20].